KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income (2018 - 2020)

Arbutus Biopharma's Equity Income history spans 3 years, with the latest figure at $2.5 million for Q4 2020.

  • On a quarterly basis, Equity Income rose 122.68% to $2.5 million in Q4 2020 year-over-year; TTM through Dec 2021 was -$45000.0, a 0.0% change, with the full-year FY2020 number at -$2.5 million, up 88.7% from a year prior.
  • Equity Income hit $2.5 million in Q4 2020 for Arbutus Biopharma, up from -$2.5 million in the prior quarter.
  • Over the last five years, Equity Income for ABUS hit a ceiling of $24.9 million in Q2 2018 and a floor of -$11.0 million in Q4 2019.
  • Historically, Equity Income has averaged -$358777.8 across 3 years, with a median of -$2.8 million in 2018.
  • Biggest five-year swings in Equity Income: tumbled 304.74% in 2019 and later soared 122.68% in 2020.
  • Tracing ABUS's Equity Income over 3 years: stood at -$2.7 million in 2018, then crashed by 304.74% to -$11.0 million in 2019, then soared by 122.68% to $2.5 million in 2020.
  • Business Quant data shows Equity Income for ABUS at $2.5 million in Q4 2020, -$2.5 million in Q3 2020, and -$11.0 million in Q4 2019.